Your browser doesn't support javascript.
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
Davis, Chris; Logan, Nicola; Tyson, Grace; Orton, Richard; Harvey, William T; Perkins, Jonathan S; Mollett, Guy; Blacow, Rachel M; Peacock, Thomas P; Barclay, Wendy S; Cherepanov, Peter; Palmarini, Massimo; Murcia, Pablo R; Patel, Arvind H; Robertson, David L; Haughney, John; Thomson, Emma C; Willett, Brian J.
  • Davis C; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Logan N; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Tyson G; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Orton R; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Harvey WT; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Perkins JS; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Mollett G; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Blacow RM; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Peacock TP; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Barclay WS; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Cherepanov P; The Francis Crick Institute, London, United Kingdom.
  • Palmarini M; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Murcia PR; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Patel AH; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Robertson DL; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Haughney J; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Thomson EC; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Willett BJ; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS Pathog ; 17(12): e1010022, 2021 12.
Article in English | MEDLINE | ID: covidwho-1546978
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Vaccines are proving to be highly effective in controlling hospitalisation and deaths associated with SARS-CoV-2 infection but the emergence of viral variants with novel antigenic profiles threatens to diminish their efficacy. Assessment of the ability of sera from vaccine recipients to neutralise SARS-CoV-2 variants will inform the success of strategies for minimising COVID19 cases and the design of effective antigenic formulations. Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines. Across all vaccinated individuals, the spike glycoproteins from B.1.617.1 and B.1.617.2 conferred reductions in neutralisation of 4.31 and 5.11-fold respectively. The reduction seen with the B.1.617.2 lineage approached that conferred by the glycoprotein from B.1.351 (South African) variant (6.29-fold reduction) that is known to be associated with reduced vaccine efficacy. Neutralising antibody titres elicited by vaccination with two doses of BNT162b2 were significantly higher than those elicited by vaccination with two doses of ChAdOx1. Fold decreases in the magnitude of neutralisation titre following two doses of BNT162b2, conferred reductions in titre of 7.77, 11.30 and 9.56-fold respectively to B.1.617.1, B.1.617.2 and B.1.351 pseudoviruses, the reduction in neutralisation of the delta variant B.1.617.2 surpassing that of B.1.351. Fold changes in those vaccinated with two doses of ChAdOx1 were 0.69, 4.01 and 1.48 respectively. The accumulation of mutations in these VOCs, and others, demonstrate the quantifiable risk of antigenic drift and subsequent reduction in vaccine efficacy. Accordingly, booster vaccines based on updated variants are likely to be required over time to prevent productive infection. This study also suggests that two dose regimes of vaccine are required for maximal BNT162b2 and ChAdOx1-induced immunity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1010022

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1010022